Senior Manager, HEOR/RWE, Voranigo
SERVIER MONDE
Summary
The Senior Manager, HEOR/RWE, is responsible for the strategic development and execution of Health Economics and Outcomes Research (HEOR) and Real-World Evidence (RWE) initiatives for Voranigo. Operating within a dynamic matrix organization, the incumbent will partner closely with key cross-functional teams—including Medical Affairs, Clinical Development, and Market Access – to drive comprehensive asset strategies. HEOR/RWE research areas will focus on unmet medical need and disease epidemiology, real-world treatment patterns, clinical and economic outcomes, patient-reported outcomes, comparative effectiveness, and overall real-world clinical practice patterns. Furthermore, this role is accountable for driving clear, impactful communication of HEOR/RWE insights, research findings, and strategic implications to internal cross-functional teams, ensuring organizational alignment and informed decision-making.
Job description
Primary Responsibilities
- Serve as the primary HEOR/RWE Subject Matter Expert (SME) for assigned oncology assets, providing deep scientific and methodological expertise to cross-functional teams.
- Collaborate with Medical Strategy teams to develop and execute on HEOR/RWE evidence strategies.
- Collaborate with clinical development teams to design and incorporate patient-reported outcomes (PRO) measures within clinical trials.
- Provide scientific expertise in the development of payer and regulatory submissions.
- Oversee the end-to-end delivery of evidence initiatives that inform access and clinical practice, partnering with Medical Strategy leads and other cross-functional scientific collaborators.
- Work with external vendors and internal teams to design and execute oncology evidence projects, ensuring timely and on-budget delivery while meeting ethical and scientific standards.
- Drive external and internal pull-through and communication of HEOR strategy and evidence to internal and external stakeholders, including cross-functional asset and governance teams, and external stakeholders.
- In collaboration with the publications team, develop the RWE/HEOR publications plan and create materials in compliance with company, industry, and regulatory requirements.
- In collaboration with the asset/indication HEOR lead, develop tactical plans for evidence generation initiatives.
- Ensure cross-functional alignment and engagement throughout study execution.
- Track and communicate project progress and budget management.
- Ensure timely measurement and communication of the external and internal impact of HEOR evidence.
Education and Required Skills
- Advanced degree (PhD, PharmD, MS) in Health Outcomes, Pharmacoeconomics, Epidemiology, or a related field, with relevant experience in oncology.
- 5+ years of work experience dependent on level of education, and at least 2+ in HEOR/RWE within the pharmaceutical industry or consulting, with experience in HEOR/RWE strategy development and execution.
- Strong project management capabilities and the ability to work in a matrix organization.
- Effective in communicating research findings and able to translate these into actionable insights for diverse internal and external stakeholders.
- Advanced technical expertise in HEOR/RWE study design and execution, and the ability to effectively communicate scientific data to varied audiences.
- High emotional intelligence and ability to build consensus, inspire collaboration, and lead through influence.
- Proactive problem-solver who thrives in a fast-paced, dynamic environment with shifting priorities.
- Strong interpersonal skills and a team-first attitude, with a demonstrated ability to work effectively across departments and cultures.
Travel and Location: Boston Based Hybrid role, 15-20% Travel.
Requirements
- Advanced degree (PhD, PharmD, MS) in Health Outcomes, Pharmacoeconomics, Epidemiology, or a related field
- Relevant experience in oncology
- 5+ years of work experience dependent on level of education
- At least 2+ years in HEOR/RWE within the pharmaceutical industry or consulting
- Experience in HEOR/RWE strategy development and execution
- Strong project management capabilities
- Ability to work in a matrix organization
- Effective in communicating research findings and translating into actionable insights
- Advanced technical expertise in HEOR/RWE study design and execution
- Ability to effectively communicate scientific data to varied audiences
- High emotional intelligence and ability to build consensus, inspire collaboration, and lead through influence
- Proactive problem-solver who thrives in a fast-paced, dynamic environment
- Strong interpersonal skills and a team-first attitude
- Demonstrated ability to work effectively across departments and cultures
Benefits
- Medical insurance
- Dental insurance
- Vision insurance
- Flexible time off
- 401(k)
- Life insurance
- Disability insurance
- Recognition programs
Company overview
Servier, officially known as Laboratoires Servier, is a leading international pharmaceutical company founded in 1954 and headquartered in Suresnes, France. As the second largest French pharmaceutical group and the leading independent French pharmaceutical company, Servier operates in close to 140 countries worldwide, with 82% of its sales generated outside France. The company specializes in three main therapeutic areas: oncology, cardiometabolism & venous diseases, and neurology, with a particular focus on becoming a significant player in oncology, especially for rare cancers. Servier is governed by a unique non-profit foundation model that preserves its independence and allows for long-term strategic vision. The company invests approximately 20% of its brand-name medicine revenue into research and development annually, employing over 22,000 people globally, including 3,000 dedicated to R&D. With revenue of €5.9 billion in 2023/2024, Servier maintains 13 production sites and 6 research centers worldwide, producing 95.8% of active ingredients for its brand-name medicines in France. The company has established itself as a world leader in cardiology and hypertension treatments while expanding its oncology portfolio through strategic acquisitions and partnerships.